Akero Therapeutics, Inc. ( AKRO )

Derivative

Common Stock

9,398^{footnote F1,F2}

-^{footnote F3}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Footnote F1 (shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F1,F2}

-^{footnote F3}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Footnote F1 (shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Common Stock

277,075^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Common Stock

159,762^{footnote F2}

-^{footnote F3}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

5,032

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

2,328

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

4,739

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

3,527

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

292,179

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

374,985

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

233,252

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

23,809

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

165,289

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

87,220

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

238,973

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

234,000

-^{footnote F4}

Dec 9, 2025

Andrew Cheng - Officer

Derivative

Stock Option (Right to Buy)

10,000

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

136,301^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Derivative

Common Stock

148,063^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F3}

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F5}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F5}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F5}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F5}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F5}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F5}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F3 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F5 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

93,000^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Derivative

Common Stock

1,200,000^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F3}

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F5}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F3 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F5 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F1,F2}

-^{footnote F3}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Footnote F1 (shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Common Stock

238,339^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Common Stock

43,810^{footnote F2}

-^{footnote F3}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

5,032

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

2,328

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

56,579

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

119,969

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

84,051

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

26,152

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

29,074

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

29,074

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

49,945

-^{footnote F4}

Dec 9, 2025

Timothy Rolph - Officer

Derivative

Stock Option (Right to Buy)

389

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F1,F2}

-^{footnote F3}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

70,587

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

11,493

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

76,227

-^{footnote F4}

Footnote F1 (shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc, a Delaware corporation and a… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Scott A. Gangloff - Officer

Derivative

Common Stock

5,088^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Scott A. Gangloff - Officer

Derivative

Common Stock

21,263^{footnote F2}

-^{footnote F3}

Dec 9, 2025

Scott A. Gangloff - Officer

Derivative

Stock Option (Right to Buy)

17,784

-^{footnote F4}

Dec 9, 2025

Scott A. Gangloff - Officer

Derivative

Stock Option (Right to Buy)

73,700

-^{footnote F4}

Dec 9, 2025

Scott A. Gangloff - Officer

Derivative

Stock Option (Right to Buy)

204,616

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU (a "Company RSU").
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

William Richard White - Officer

Derivative

Common Stock

10,179^{footnote F1}

-^{footnote F1}

Dec 9, 2025

William Richard White - Officer

Derivative

Common Stock

47,573^{footnote F2}

-^{footnote F3}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

5,032

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

2,328

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

4,739

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

3,527

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

18,964

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

70,279

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

116,833

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

83,400

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

84,051

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

82,482

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

29,074

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

29,074

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

29,073

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

74,053

-^{footnote F4}

Dec 9, 2025

William Richard White - Officer

Derivative

Stock Option (Right to Buy)

24,745

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Catriona Yale - Officer

Derivative

Common Stock

27,227^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Common Stock

47,573^{footnote F2}

-^{footnote F3}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

5,032

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

2,328

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

70,279

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

131,205

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

84,051

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

33,421

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

74,053

-^{footnote F4}

Dec 9, 2025

Catriona Yale - Officer

Derivative

Stock Option (Right to Buy)

52,785

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Common Stock

3,059^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Common Stock

26,832^{footnote F2}

-^{footnote F3}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F4}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

382

-^{footnote F4}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

11,096

-^{footnote F4}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

48,679

-^{footnote F4}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

64,182

-^{footnote F4}

Dec 9, 2025

Patrick Lamy - Officer

Derivative

Stock Option (Right to Buy)

84,904

-^{footnote F4}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Derivative

Common Stock

9,398^{footnote F1,F2}

-^{footnote F3}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

26,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

15,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

13,000

-^{footnote F4}

Dec 9, 2025

Derivative

Stock Option (Right to Buy)

11,797

-^{footnote F4}

Footnote F1 (shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F2 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
Footnote F3 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Dec 9, 2025

Jonathan Young - Officer

Derivative

Common Stock

152,616^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Common Stock

20,000^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Common Stock

20,000^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Common Stock

20,000^{footnote F1}

-^{footnote F1}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Common Stock

47,573^{footnote F3}

-^{footnote F4}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

3,421

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

5,032

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

2,328

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

70,279

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

141,205

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

84,051

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

29,073

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

29,074

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

44,982

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

28,584

-^{footnote F5}

Dec 9, 2025

Jonathan Young - Officer

Derivative

Stock Option (Right to Buy)

74,053

-^{footnote F5}

Footnote F1 (price, shares): This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to… Full note on SEC EDGAR
Footnote F3 (shares): Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
Footnote F4 (price): Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
Footnote F5 (price): Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to… Full note on SEC EDGAR

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

3,527

$28.35

$100K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

43,064

$6.36

$274K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

4,284

$21.09

$90K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

2,796

$0.62

$2K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

94,268

$0.62

$58K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Common Stock

4,739

$21.10

$100K

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

2,796

$0.00

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

94,268

$0.00

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

43,064

$0.00

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

4,284

$0.00

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

3,527

$0.00

Nov 25, 2025

Timothy Rolph - Officer

Option exercise

Stock Option (Right to Buy)

4,739

$0.00

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Common Stock

4,284

$21.09

$90K

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Common Stock

3,527

$28.35

$100K

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Common Stock

4,739

$21.10

$100K

Nov 26, 2025

Jonathan Young - Officer

Gift

Common Stock

9,259

$0.00

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Stock Option (Right to Buy)

4,284

$0.00

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Stock Option (Right to Buy)

3,527

$0.00

Nov 24, 2025

Jonathan Young - Officer

Option exercise

Stock Option (Right to Buy)

4,739

$0.00

Nov 20, 2025

Andrew Cheng - Officer

Gift

Common Stock

74,538

$0.00

Nov 17, 2025

Timothy Rolph - Officer

Gift

Common Stock

37,100

$0.00

Nov 12, 2025

Andrew Cheng - Officer

Gift

Common Stock

14,739

$0.00

Nov 4, 2025

Catriona Yale - Officer

Option exercise

Common Stock

3,527

$28.35

$100K

Nov 4, 2025

Catriona Yale - Officer

Option exercise

Common Stock

4,739

$21.10

$100K

Nov 4, 2025

Catriona Yale - Officer

Option exercise

Stock Option (Right to Buy)

3,527

$0.00

Nov 4, 2025

Catriona Yale - Officer

Option exercise

Stock Option (Right to Buy)

4,739

$0.00

Oct 10, 2025

Andrew Cheng - Officer

Option exercise

Common Stock

30,000

$19.87

$596K

Oct 10, 2025

Andrew Cheng - Officer

Open-market sale

Common Stock

30,000

$53.98^{footnote F2}

$1.62M

Oct 10, 2025

Andrew Cheng - Officer

Option exercise

Stock Option (Right to Buy)

30,000

$0.00

Footnote F2 (price): The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.92 to $54.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the… Full note on SEC EDGAR

Oct 8, 2025

Option exercise

Common Stock

26,000

$23.02

$599K

Oct 8, 2025

Option exercise

Common Stock

15,000

$8.13

$122K

Oct 8, 2025

Option exercise

Common Stock

13,000

$26.32

$342K

Oct 8, 2025

Option exercise

Common Stock

13,000

$25.20

$328K

Oct 8, 2025

Option exercise

Common Stock

23,832

$19.97

$476K

Oct 8, 2025

Option exercise

Stock Option (Right to Buy)

26,000

$0.00

Oct 8, 2025

Option exercise

Stock Option (Right to Buy)

15,000

$0.00

Oct 8, 2025

Option exercise

Stock Option (Right to Buy)

13,000

$0.00

Oct 8, 2025

Option exercise

Stock Option (Right to Buy)

13,000

$0.00

Oct 8, 2025